【市场】大涨126%独家呼吸系统中成药，康缘申请保护

米内网2025-08-07

精彩内容8月6日，国家药监局官网显示，散寒化湿颗粒申请中药品种保护初保获受理。该产品是江苏康缘药业的独家品种，米内网数据显示，散寒化湿颗粒在2025年一季度中国三大终端六大市场（统计范围见文末）销售额同比增长126.32%。散寒化湿颗粒功能主治为散寒化湿、宣肺透邪、辟秽化浊、解毒通络，用于寒湿郁肺所致疫病，症见发热，乏力，周身酸痛，咳嗽，咯痰，胸闷憋气，纳呆，恶心，呕吐，腹泻，大便粘腻不爽；舌质淡...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2557557488?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-07 17:12","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2557557488","market":"sh","top_or_hot":-1,"title":"【市场】大涨126%独家呼吸系统中成药，康缘申请保护","media":"米内网","content":"<div>\n<p>精彩内容8月6日，国家药监局官网显示，散寒化湿颗粒申请中药品种保护初保获受理。该产品是江苏康缘药业的独家品种，米内网数据显示，散寒化湿颗粒在2025年一季度中国三大终端六大市场（统计范围见文末）销售额同比增长126.32%。散寒化湿颗粒功能主治为散寒化湿、宣肺透邪、辟秽化浊、解毒通络，用于寒湿郁肺所致疫病，症见发热，乏力，周身酸痛，咳嗽，咯痰，胸闷憋气，纳呆，恶心，呕吐，腹泻，大便粘腻不爽；舌质淡...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807172200a6d8732f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【市场】大涨126%独家呼吸系统中成药，康缘申请保护</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【市场】大涨126%独家呼吸系统中成药，康缘申请保护\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-07 17:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807172200a6d8732f&s=b><strong>米内网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>精彩内容8月6日，国家药监局官网显示，散寒化湿颗粒申请中药品种保护初保获受理。该产品是江苏康缘药业的独家品种，米内网数据显示，散寒化湿颗粒在2025年一季度中国三大终端六大市场（统计范围见文末）销售额同比增长126.32%。散寒化湿颗粒功能主治为散寒化湿、宣肺透邪、辟秽化浊、解毒通络，用于寒湿郁肺所致疫病，症见发热，乏力，周身酸痛，咳嗽，咯痰，胸闷憋气，纳呆，恶心，呕吐，腹泻，大便粘腻不爽；舌质淡...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807172200a6d8732f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807172200a6d8732f&s=b","article_id":"2557557488","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807172200a6d8732f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2557557488","pubTimestamp":1754557964,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"精彩内容8月6日，国家药监局官网显示，散寒化湿颗粒申请中药品种保护初保获受理。散寒化湿颗粒市场准入情况来源：米内网一键检索散寒化湿颗粒是国家医保乙类品种，该产品在2025年一季度中国三大终端六大市场销售额同比增长126.32%。日前，公司发布公告，其中药1.1类新药参蒲颗粒获批上市，该产品用于盆腔炎性疾病后遗症引起的慢性盆腔痛中医辨证属湿热瘀阻证。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600557":"康缘药业","BK0028":"国家队","BK0239":"医药制造","BK0188":"融资融券"},"translate_title":"[Market] Soared 126% Exclusive respiratory system ready-for-use traditional Chinese medicine, Kangyuan applied for protection","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600557":0.9},"content_text":"精彩内容8月6日，国家药监局官网显示，散寒化湿颗粒申请中药品种保护初保获受理。该产品是江苏康缘药业的独家品种，米内网数据显示，散寒化湿颗粒在2025年一季度中国三大终端六大市场（统计范围见文末）销售额同比增长126.32%。散寒化湿颗粒功能主治为散寒化湿、宣肺透邪、辟秽化浊、解毒通络，用于寒湿郁肺所致疫病，症见发热，乏力，周身酸痛，咳嗽，咯痰，胸闷憋气，纳呆，恶心，呕吐，腹泻，大便粘腻不爽；舌质淡胖齿痕或淡红，舌苔白厚腻、或腐腻，脉滑或濡。散寒化湿颗粒市场准入情况来源：米内网一键检索散寒化湿颗粒是国家医保乙类品种，该产品在2025年一季度中国三大终端六大市场销售额同比增长126.32%。据了解，康缘药业主要产品线聚焦呼吸与感染疾病、心脑血管疾病、妇科疾病、骨伤科疾病等中医优势领域同时，积极拓展其他中药治疗领域；化药领域仿创结合，在心脑血管疾病、呼吸系统疾病、消化系统疾病等治疗领域积极布局，培育出多个化药类型注射和口服剂型产品，进一步丰富产品管线；生物药领域已陆续布局，覆盖肿瘤、代谢性疾病、自身免疫疾病、神经系统疾病等治疗领域。日前，公司发布公告，其中药1.1类新药参蒲颗粒获批上市，该产品用于盆腔炎性疾病后遗症引起的慢性盆腔痛中医辨证属湿热瘀阻证。今年以来受理的中药品种保护申请今年以来，国家药监局官网共发布15个中药保护品种受理公示，多个独家品种在列，包括江苏康缘药业的散寒化湿颗粒、重庆华森制药的痛泻宁颗粒、株洲千金药业的补血益母丸、山东步长神州制药的康妇炎胶囊等，涵盖呼吸系统用药、消化系统疾病用药等多个治疗大类。资料来源：国家药监局官网、米内网数据库等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557557488","isCrawlerRequest":true}